Pharmanutra Logo

Pharmanutra

Researches and markets nutritional supplements & medical devices for all ages.

PHN | XMIL

Overview

Corporate Details

ISIN(s):
IT0005274094
LEI:
815600F8217BC7733697
Country:
Italy
Address:
VIA CAMPODAVELA, 1, 56122 PISA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 2003, PharmaNutra is a company specializing in the research, development, and marketing of nutritional supplements and medical devices. The firm emphasizes scientific innovation and manages the entire production process, from proprietary raw materials to finished goods. Through its in-house research centers and labs, it pioneers studies to create unique and effective products. The portfolio focuses on addressing nutritional deficiencies, such as minerals and vitamins, and supporting musculoskeletal and joint health for consumers of all ages.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-20 08:50
Regulatory News Service
Italian Roadshow 2025 - Paris
Italian 5.4 MB
2025-11-14 10:19
Regulatory News Service
INTERIM MANAGEMENT REPORT AS AT SEPTEMBER 30, 2025
Italian 1.7 MB
2025-11-14 10:17
Regulatory News Service
Resoconto intermedio di gestione al 30 settembre 2025
Italian 1.7 MB
2025-11-13 09:58
Regulatory News Service
Interim Management report as at September 30 2025
Italian 1.8 MB
2025-11-13 09:56
Regulatory News Service
Resoconto Intermedio di gestione al 30 settembre 2025
Italian 1.7 MB
2025-11-13 09:54
Regulatory News Service
Avviso deposito Rendiconto Intermedio di gestione al 30 settembre 2025 || Notic…
Italian 225.3 KB
2025-11-10 17:51
Earnings Release
PHARMANUTRA S.P.A.: BOARD OF DIRECTORS APPROVES THE INTERIM MANANGEMENT REPORT …
English 338.9 KB
2025-11-10 17:49
Earnings Release
PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTE…
Italian 342.0 KB
2025-11-04 11:34
Director's Dealing
ALLEGATO 3F - OTTOBRE 2025
Italian 93.2 KB
2025-10-20 08:00
Regulatory News Service
“SIDERAL® FORTE” PREMIATO COME MIGLIOR PRODOTTO NUTRACEUTICO || “SIDERAL® FORTE…
Italian 278.3 KB
2025-10-03 13:13
Transaction in Own Shares
Initiation of share buy-back program
English 243.9 KB
2025-10-03 13:12
Transaction in Own Shares
Avvio del programma di acquisti di azioni proprie
Italian 232.8 KB
2025-10-01 09:00
Investor Presentation
Eccellenze del Made in Italy | Presentazione
English 5.0 MB
2025-09-12 10:35
Interim Report
Half Year Financial Report 2025
English 3.3 MB
2025-09-12 10:34
Interim Report
Relazione finanziaria semestrale 2025
Italian 3.4 MB

Automate Your Workflow. Get a real-time feed of all Pharmanutra filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharmanutra

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharmanutra via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BOIRON Logo
Global manufacturer of homeopathic medicines for pain relief and flu-like symptoms, sold worldwide.
France
BOI
Bon Natural Life Ltd Logo
Bio-manufactures natural plant ingredients for fragrances, supplements, and immunity solutions.
United States of America
BON
Bosnalijek d.d. Sarajevo Logo
Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.
Bosnia and Herzegovina
BSNL
Boundless Bio, Inc. Logo
Developing ecDNA-directed therapies for intractable oncogene amplified cancers.
United States of America
BOLD
BridgeBio Oncology Therapeutics, Inc. Logo
Clinical-stage biopharma creating small molecule drugs for RAS-dependent cancers.
United States of America
BBOT
BridgeBio Pharma, Inc. Logo
Develops transformative medicines for genetic diseases and genetically driven cancers.
United States of America
BBIO
BRIGHT MINDS BIOSCIENCES INC. Logo
Developing next-gen serotonergic drugs for neurological and psychiatric disorders like epilepsy.
United States of America
DRUG
BRISTOL MYERS SQUIBB CO Logo
Develops innovative medicines for oncology, immunology, and cardiovascular diseases.
United States of America
BMY
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea
003000
Burning Rock Biotech Ltd Logo
Offers NGS-based diagnostics for precision oncology, from detection to clinical trial support.
United States of America
BNR

Talk to a Data Expert

Have a question? We'll get back to you promptly.